The yellow-tinted IOLs were equivalent to the clear IOLs in postoperative contrast sensitivity, visual acuity, and color perception under photopic conditions. Patients with yellow-tinted IOLs made statistically significantly more mistakes in the blue range under dim light than patients with clear IOLs.
. Purpose: To evaluate the safety and efficacy of intravitreal bevacizumab therapy for early and advanced neovascular age‐related macular degeneration (ARMD). Methods: A consecutive series of eyes with neovascular ARMD treated with monthly intravitreal injections of bevacizumab (1.25 mg/0.05 ml) as long as there was evidence of activity on fluorescein angiography (FA) and optical coherence tomography (OCT) was included and observed for 6 months. For further analysis they were assigned to either an early (untreated/newly diagnosed) or an advanced (predominantly fibrotic/pre‐treated) ARMD group. We examined distance visual acuity (VA) with Early Treatment Diabetic Retinopathy Study (ETDRS) charts and central retinal thickness with OCT, as well as lesion size and safety aspects. Results: Forty‐four patients (44 eyes) were enrolled (21 early lesions, 23 advanced lesions). Mean VA changed from 0.74 logMAR at baseline to 0.68 logMAR at month 6 (P = 0.01). Improvement in VA was statistically significant only in eyes with early lesions (n = 21) from month 1 (P = 0.015) up to month 6 (P = 0.03). The changes in central retinal thickness (CRT) (P < 0.001) and total lesion size (P < 0.001) were significant in both groups (early and advanced) at all time‐points during follow‐up. No significant ocular or systemic adverse effects were observed. Conclusion: Intravitreal bevacizumab was tolerated well by our patients and we did not identify any apparent short‐term safety concerns. We observed stabilization in VA overall, with significant improvement in the early lesion group.
Background: Epidemiological screening to examine possible ultraviolet-induced ocular changes and pathologies in Austrian farmers. Methods: The study was performed on behalf of the Austrian farmer insurance (Sozialversicherungsanstalt der Bauern). Randomly selected farmers and office workers as controls, both at the age of 35–55 years, underwent ophthalmic screening examinations. All subjects underwent complete ophthalmic examinations by slit lamp examination and Schirmer’s test 1. A survey, regarding per- sonal habits in the sun, was also conducted. Results: Three hundred and ninety-two subjects underwent ophthalmic examinations of whom 297 were farmers and 95 were controls. Due to the survey, 89.7% of the farmers claimed to protect themselves from the sun during work. From these subjects, 83.7% wear a head protection, 71.0% wear sunglasses, and 54.4% usually work in the shade. There were significant differences in lid (p = 0.021) and conjunctival pathologies (p < 0.0001) between farmers and controls. Conclusion: Austrian farmers are at a higher risk for developing lid and conjunctival tumours which require treatment at some point. We believe that the study group was too young to show significant differences within the lens and the posterior pole. A 5-year follow-up is planned.
Zusammenfassung.Hintergrund: Die Kombination von Keratopathie and Ablatio retinae -verursacht durch Degeneration bzw. Trauma -fiihrt unbehandelt zur Erblindung and haufig zu einer Phthisis, aus der sich oft die Indikation zur Enukleation ergibt. Eine der wenigen Therapieoptionen stellt die Operation mittels temporarer Keratoprothese (EckardtProthese), Homhauttransplantation and hinterer Augenabschnittsrekonstruktion dar.Material and Methode: In einer retrospektiven Analyse untersuchten wir den primaren operativen Outcome sowie die Langzeitergebnisse dieser Methode der im Zeitraum von 1996-2002 an der Abteilung operierten Patienten. 15 Patienten im mittleren Alter von 53 f 17 Jahre (m/w: 9/6) wurden inkludiert.Resultate: Postoperativ konnte der Visus von 0,0005 ± 0,0005 auf 0,0172 ± 0,0509 signifikant verbessert werden (p = 0,04). Die preoperative Keratopathie konnte mittels Transplantat primer bei allen (100%) and die Ablatio retinae bei 14 (93%) Patienten saniert werden. Nach einer mittleren Beobachtungsperiode von 1,8 Jahren betrug der Visus 0,0062 ± 0,0144 (p = 0,07 vs. praoperativ). 9 (60%) Patienten hatten eine rezidivierende Hornhauttrubung bzw. 2 (13%) eine Netzhautablosung. Bei 2 (13%) Patienten konnte das Auge nicht erhalten werden.Schlussfolgerung: Diese Studie zeigt, dass die unmittelbaren Ergebnisse Behr gut sind, in der Langzeitbeobachtung jedoch etwas absinken. Trotzdem ist auch hier ein Organerhalt and ein funktioneller Anstieg in einem hohen Prozentsatz moglich.Schlasselworter: Temporare Keratoprothese, Keratopathie, Ablatio retinae. Long-term results after temporary keratoprosthesis for keratopathy and retinal detachmentSummary. Background: Severe ocular lesion with keratopathy and retinal detachment caused by degeneration or trauma is often followed by amaurosis and phthisis, which can finally result in enucleation. One of the few therapeutic options is the combined surgery with the use of a temporary keratoprosthesis (Eckardt-Prosthesis), reconstruction of the posterior segment and corneal transplantation.Material and methods: In a retrospective analysis we examined the primary surgical outcome of this method and long term results of all operated patients between 1996-2002. 15 patients were included in this study with an average age of 53 f 17 years (m/f: 9/6).Results: The postoperative visual acuity could be significantly improved from 0.0005 + 0.0005 before surgery to 0.0172 ± 0.0509 (p < 0.04). The preoperative existing keratopathy was primary cured by corneal transplantation in all eyes (100%) and the retinal detachment cured in 14 (93%) cases. After a mean observation time of 1.8 years the visual acuity was 0.0062 ± 0.0144 (p = 0.07 vs. preoperative). Although it was lower than postoperative, it was still better then preoperative. 9 (60%) of the patients had developed a keratopathy and 2 (13%) a retinal detachment. In 2 (13%) cases enucleation of the eye became necessary.Conclusion: This study shows, that the postoperative results were very good, even the longterm results showed a tenden...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.